Intravitreal injection of tissue plasminogen activator as treatment for an occluded pars plana glaucoma tube

Irena TsuiDepartment of Ophthalmology, Columbia University, New York, NY, USA

Suzanna AirianiDepartment of Ophthalmology, Columbia University, New York, NY, USA

Angie WenDepartment of Ophthalmology, Columbia University, New York, NY, USA

Tarek El-SawyDepartment of Ophthalmology, Columbia University, New York, NY, USA

Howard F FineDepartment of Ophthalmology, Columbia University, New York, NY, USA

Peter JG Maris JrDepartment of Ophthalmology, Columbia University, New York, NY, USACorrespondence[email protected]

References

Al-TorbakAGraft survival and glaucoma outcome after simultaneous penetrating keratoplasty and Ahmed Glaucoma Valve implantCornea200322194712658081
PubMed Web of Science ®Google Scholar
RitterbandDCShapiroDTrubnikVPenetrating keratoplasty with pars plana glaucoma drainage devicesCornea2007261060617893534
PubMed Web of Science ®Google Scholar
SzymanskiAPromotion of glaucoma filter bleb with tissue plasminogen activator after sclerectomy under a clotInt Ophthalmol199216387901428577
PubMed Web of Science ®Google Scholar
ZaltaAHSweeneyCPZaltaAKIntracameral tissue plasminogen activator use in a large series of eyes with valved glaucoma drainage implantsArch Ophthalmol200212014879312427061
PubMedGoogle Scholar
KameiMEstafanousMLewisHTissue plasminogen activator in the treatment of vitreoretinal diseasesSemin Ophthalmol200015445010749314
PubMedGoogle Scholar
ChenSNYangTCHoCLRetinal toxicity of intravitreal tissue plasminogen activator: case report and literature reviewOphthalmology2003110704812689889
PubMed Web of Science ®Google Scholar
HrachCJJohnsonMWHassanASRetinal toxicity of commercial intravitreal tissue plasminogen activator solution in cat eyesArch Ophthalmol20001186596310815158
PubMedGoogle Scholar